Understanding Patient Preferences in Neuroendocrine Tumor Treatments

When you meet with your healthcare team do you discuss what is important to you as you consider neuroendocrine tumor treatment options?  You can help physicians better understand patient-centered treatment decision making by participating in this new survey, DIRECT NETs, available through November 5, 2020.

DIRECT NETs, an international study, uses an innovative survey that involves making a series of choices between potential treatments with different characteristics. The study will enhance doctors’ understanding of why different people prefer the various medications that are used to treat NETs.Survey, DIRECT-NETs_2, Sept 2020_border2

DIRECT-NETs is an online, self-administered anonymous survey that takes less than 15 minutes to complete. It is open to:

  • NET patients
  • Families and friends of NET patients who have been involved in their journey
  • Healthcare professionals involved in the care of NET patients

The DIRECT NETs study has just launched and the survey will be available through November 5th, 2020.

DIRECT NETs is being conducted under the auspices of CommNETS, the Commonwealth Neuroendocrine Tumour Collaboration.

You can find out more about the study, and self-enroll if you are interested, at the following website: Direct-NETs.com


CommNETs logo png (002)

Print Friendly, PDF & Email